Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Grass Pollen Allergy Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Grass Pollen Allergy Overview | 7 | 1 |
| Grass Pollen Allergy Therapeutics under Development by Companies | 8 | 1 |
| Grass Pollen Allergy Pipeline Products Glance | 9 | 2 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Grass Pollen Allergy Products under Development by Companies | 11 | 1 |
| Grass Pollen Allergy Companies Involved in Therapeutics Development | 12 | 7 |
| ALK-Abello A/S | 12 | 1 |
| Allergy Therapeutics Plc | 13 | 1 |
| Biomay AG | 14 | 1 |
| Circassia Pharmaceuticals Plc | 15 | 1 |
| HAL Allergy BV | 16 | 1 |
| Roxall Medizin GmbH | 17 | 1 |
| Shionogi &Co., Ltd. | 18 | 1 |
| Grass Pollen Allergy Therapeutics Assessment | 19 | 8 |
| Assessment by Monotherapy Products | 19 | 1 |
| Assessment by Target | 20 | 2 |
| Assessment by Mechanism of Action | 22 | 1 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 2 |
| Drug Profiles | 27 | 15 |
| Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis Drug Profile | 27 | 1 |
| Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis Drug Profile | 28 | 1 |
| asapiprant Drug Profile | 29 | 1 |
| BM-32 Drug Profile | 30 | 3 |
| clustoid wiesenlieschgras Drug Profile | 33 | 1 |
| Pollinex Quattro Grass Drug Profile | 34 | 3 |
| standardized grass pollen [timothy (Phleum pratense)] allergen extract Drug Profile | 37 | 3 |
| Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma Drug Profile | 40 | 2 |
| Grass Pollen Allergy Dormant Projects | 42 | 1 |
| Grass Pollen Allergy Product Development Milestones | 43 | 12 |
| Featured News &Press Releases | 43 | 1 |
| Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204 | 43 | 1 |
| Jun 13, 2016: New Data From GAP Landmark Trial Confirm GRAZAX Prevents Asthma Symptoms in Children | 43 | 2 |
| May 25, 2016: Circassia Initiates Grass Allergy Immunotherapy Registration Study | 45 | 1 |
| Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL | 46 | 1 |
| Jan 28, 2016: Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32 | 47 | 1 |
| Jan 14, 2016: ALK announces top-line results from the five-year landmark GRAZAX Asthma Prevention trial in children | 47 | 1 |
| Jun 03, 2015: Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference. | 48 | 1 |
| Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32 | 49 | 1 |
| Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK | 49 | 1 |
| Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study | 50 | 1 |
| Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) | 51 | 1 |
| Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32 | 51 | 1 |
| Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK | 51 | 1 |
| Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet | 52 | 1 |
| Nov 09, 2013: Merck s Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study | 53 | 2 |
| Appendix | 55 | 2 |
| Methodology | 55 | 1 |
| Coverage | 55 | 1 |
| Secondary Research | 55 | 1 |
| Primary Research | 55 | 1 |
| Expert Panel Validation | 55 | 1 |
| Contact Us | 55 | 1 |
| Disclaimer | 56 | 1 |
